Investor Foresite Capital Fund V, L.P.
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Foresite Capital Fund V, L.P. . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Date Form Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2024-04-05 13D/A KNTE / Kinnate Biopharma Inc. 13,779,062 0
2024-02-22 13D/A KNTE / Kinnate Biopharma Inc. 13,779,062 13,779,062
2024-02-05 13G CGON / CG Oncology, Inc. 3,595,203
2023-11-24 13D/A INVA / Innoviva, Inc. 5,494,621 5,494,621
2023-11-17 13D/A KNTE / Kinnate Biopharma Inc. 13,779,062 13,779,062
2023-11-14 13D/A KNTE / Kinnate Biopharma Inc. 13,779,062
2023-07-19 13D/A INVA / Innoviva, Inc. 4,794,621 5,494,621
2023-02-13 13G/A CMPX / Compass Therapeutics, Inc. 5,500,000 5,954,250
2023-01-03 13D/A / THESEUS PHARMACEUTICALS INC 4,294,621 4,794,621
2022-06-13 13D/A / THESEUS PHARMACEUTICALS INC 3,681,552 4,294,621
2022-02-11 13G/A PHICU / Population Health Investment Co Inc - Units (1 Ord Share Class A & 1/3 War) 0
2022-02-11 13G/A LSAQ / LifeSci Acquisition II Corp 500,000 0
2022-02-11 13G/A CGEM / Cullinan Therapeutics, Inc. 3,641,879 1,524,008
2021-11-12 13G CMPX / Compass Therapeutics, Inc. 5,500,000
2021-10-18 13D / THESEUS PHARMACEUTICALS INC 3,681,552
2021-01-15 13G CGEM / Cullinan Therapeutics, Inc. 3,641,879
2020-11-25 13G LSAQ / LifeSci Acquisition II Corp 500,000